Jinlin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jinlin Wang has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
Yunxiang Zeng
Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University
15 shared publicationsNaijian Li
Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital, Guangzhou Medical University
10 shared publications- Jianxing He
Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
5 shared publications Panxiao Shen
Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
5 shared publicationsShaowei Liu
Department of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
5 shared publicationsWeifeng Wei
Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital Guangzhou Medical University Guangzhou People's Republic of China
5 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1979193
Eosinophils in cancer immunity: context-dependent plasticity, biomarker potential, and therapeutic opportunities
Eosinophils, traditionally associated with type 2 immunity, are increasingly recognized as context-dependent regulators of cancer immunity. Their effects are not intrinsically anti-tumorigenic or pro-tumorigenic but are shaped by five partially distinct dimensions of context: tumor type and stage, anatomical compartment and microlocalization, cytokine milieu and activation state, the circulating-versus-tissue compartment, and treatment exposure. This Review critically synthesizes mechanistic and clinical evidence defining this functional plasticity, with explicit separation of murine and human evidence throughout. Eosinophils can directly kill tumor cells through granule proteins and reactive oxygen species, recruit and activate cytotoxic lymphocytes, promote vascular normalization, and participate in interleukin-33-dependent anti-tumor circuits. In other settings, they can facilitate metastatic dissemination, angiogenesis, tissue remodeling, and immune suppression. These opposing functions help explain the heterogeneous clinical associations reported across malignancies. Tissue eosinophils at the invasive tumor front are associated with longer time to recurrence in colorectal cancer, whereas peripheral eosinophil dynamics have emerged as candidate biomarkers during immune checkpoint inhibitor therapy in non-small cell lung cancer; eosinophilic malignant pleural effusion may also define a distinct prognostic subgroup. We critically distinguish prognostic, predictive, and pharmacodynamic biomarker claims, and emphasize that most reported associations remain prognostic rather than demonstrated predictors of treatment benefit. We further discuss therapeutic opportunities involving the interleukin-5/interleukin-33/eotaxin axis, induced eosinophils, and eosinophil-assisted cellular therapy, graded by their level of clinical maturity and weighed against the risks of systemic eosinophil activation. We argue that clinically useful eosinophil biomarkers will require integration of abundance with phenotype, spatial localization, tissue compartment, and treatment context. This framework clarifies when eosinophils are protective, harmful, or therapeutically exploitable and highlights priorities for prospective human studies in cancer immunology and precision immunotherapy.
- 12 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1979193
Open AccessEosinophils in cancer immunity: context-dependent plasticity, biomarker potential, and therapeutic opportunities
Eosinophils, traditionally associated with type 2 immunity, are increasingly recognized as context-dependent regulators of cancer immunity. Their effects are not intrinsically anti-tumorigenic or pro-tumorigenic but are shaped by five partially distinct dimensions of context: tumor type and stage, anatomical compartment and microlocalization, cytokine milieu and activation state, the circulating-versus-tissue compartment, and treatment exposure. This Review critically synthesizes mechanistic and clinical evidence defining this functional plasticity, with explicit separation of murine and human evidence throughout. Eosinophils can directly kill tumor cells through granule proteins and reactive oxygen species, recruit and activate cytotoxic lymphocytes, promote vascular normalization, and participate in interleukin-33-dependent anti-tumor circuits. In other settings, they can facilitate metastatic dissemination, angiogenesis, tissue remodeling, and immune suppression. These opposing functions help explain the heterogeneous clinical associations reported across malignancies. Tissue eosinophils at the invasive tumor front are associated with longer time to recurrence in colorectal cancer, whereas peripheral eosinophil dynamics have emerged as candidate biomarkers during immune checkpoint inhibitor therapy in non-small cell lung cancer; eosinophilic malignant pleural effusion may also define a distinct prognostic subgroup. We critically distinguish prognostic, predictive, and pharmacodynamic biomarker claims, and emphasize that most reported associations remain prognostic rather than demonstrated predictors of treatment benefit. We further discuss therapeutic opportunities involving the interleukin-5/interleukin-33/eotaxin axis, induced eosinophils, and eosinophil-assisted cellular therapy, graded by their level of clinical maturity and weighed against the risks of systemic eosinophil activation. We argue that clinically useful eosinophil biomarkers will require integration of abundance with phenotype, spatial localization, tissue compartment, and treatment context. This framework clarifies when eosinophils are protective, harmful, or therapeutically exploitable and highlights priorities for prospective human studies in cancer immunology and precision immunotherapy.
- Open Access
- 26 October 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e004545
Clinical characterisation and therapeutic insights from a single-centre cohort of seven patients with Gorham-Stout disease
Background Gorham-Stout disease (GSD) is an ultra-rare disorder of progressive osteolysis and lymphatic proliferation, with poorly defined clinical features, optimal imaging and treatment. This study characterises the clinical spectrum, imaging findings and therapeutic responses in a single-centre GSD cohort.Methods We retrospectively analysed seven patients with GSD at the National Center for Respiratory Medicine (2019–2024). Data included demographics, clinical presentation, laboratory, pathology, multimodality imaging (CT, bone scintigraphy, 18F-fluorodeoxyglucose (18F-FDG) and 18F-fibroblast activation protein inhibitor (18F-FAPI) positron emission tomography (PET)/CT, lymphoscintigraphy) and follow-up.Results Patients (six males, one female; median age 27 years) commonly presented with dyspnoea (5/7) and universal pleural effusion (7/7, including four chylothoraces). Extensive osteolysis (ribs, spine, pelvis) occurred without significant bone pain in most cases. 18F-FAPI PET/CT showed intense uptake (maximum standardised uptake value (SUVmax) 4.0–17.6) in lesions, superior to 18F-FDG PET/CT (SUVmax<2.5 in 6/7). Lymphoscintigraphy confirmed central lymphatic leakage in all tested patients. Histopathology revealed D2-40-positive lymphatic proliferation. Individualised treatment included sirolimus (one patient, clinical and radiological improvement), alendronate (one patient, stable disease) and supportive care (five patients, symptomatic improvement over a 15-month median follow-up).Conclusions GSD often presents with chylothorax and respiratory symptoms rather than bone pain. 18F-FAPI PET/CT is superior to FDG for assessing activity and monitoring response. Whether mammalian target of rapamycin inhibition or antiresorptive therapy improves outcomes cannot be determined from this small series; our single-patient observations with sirolimus and alendronate are hypothesis-generating only. Multidisciplinary, individualised management with advanced imaging is essential.
- 26 October 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e004545
Open AccessClinical characterisation and therapeutic insights from a single-centre cohort of seven patients with Gorham-Stout disease
Background Gorham-Stout disease (GSD) is an ultra-rare disorder of progressive osteolysis and lymphatic proliferation, with poorly defined clinical features, optimal imaging and treatment. This study characterises the clinical spectrum, imaging findings and therapeutic responses in a single-centre GSD cohort.Methods We retrospectively analysed seven patients with GSD at the National Center for Respiratory Medicine (2019–2024). Data included demographics, clinical presentation, laboratory, pathology, multimodality imaging (CT, bone scintigraphy, 18F-fluorodeoxyglucose (18F-FDG) and 18F-fibroblast activation protein inhibitor (18F-FAPI) positron emission tomography (PET)/CT, lymphoscintigraphy) and follow-up.Results Patients (six males, one female; median age 27 years) commonly presented with dyspnoea (5/7) and universal pleural effusion (7/7, including four chylothoraces). Extensive osteolysis (ribs, spine, pelvis) occurred without significant bone pain in most cases. 18F-FAPI PET/CT showed intense uptake (maximum standardised uptake value (SUVmax) 4.0–17.6) in lesions, superior to 18F-FDG PET/CT (SUVmax<2.5 in 6/7). Lymphoscintigraphy confirmed central lymphatic leakage in all tested patients. Histopathology revealed D2-40-positive lymphatic proliferation. Individualised treatment included sirolimus (one patient, clinical and radiological improvement), alendronate (one patient, stable disease) and supportive care (five patients, symptomatic improvement over a 15-month median follow-up).Conclusions GSD often presents with chylothorax and respiratory symptoms rather than bone pain. 18F-FAPI PET/CT is superior to FDG for assessing activity and monitoring response. Whether mammalian target of rapamycin inhibition or antiresorptive therapy improves outcomes cannot be determined from this small series; our single-patient observations with sirolimus and alendronate are hypothesis-generating only. Multidisciplinary, individualised management with advanced imaging is essential.
- Open Access
- 2 February 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (2) , e70484
Primary Mediastinal Malignant Melanoma Presenting With Pleural Effusion: A Case Report
Background: Primary mediastinal malignant melanoma (PMMM) presenting with pleural effusion as the initial manifestation is exceedingly rare, presenting significant diagnostic and therapeutic challenges. This article reports a case of PMMM that initially manifested as pleural effusion and includes a review of the relevant literature. Case: The patient was admitted with pleural effusion and an anterior mediastinal mass. A pleural biopsy and fine‐needle aspiration of the mediastinal mass led to a pathological diagnosis of malignant melanoma. Ultimately, based on clinical findings, a final diagnosis of PMMM was established. The patient subsequently developed pleural hemorrhage; although hemostasis was achieved through thoracoscopy, his condition stabilized only temporarily. He ultimately succumbed to lung infection and multiple organ failure. Conclusion: PMMM presenting with pleural effusion lacks distinct clinical features, highlighting the importance of pathological diagnosis. Pleural hemorrhage associated with pleural metastasis may be a characteristic feature, and the prognosis for such cases is poor. Enhanced recognition and early intervention are essential to improve outcomes.
- 2 February 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (2) , e70484
Open AccessPrimary Mediastinal Malignant Melanoma Presenting With Pleural Effusion: A Case Report
Background: Primary mediastinal malignant melanoma (PMMM) presenting with pleural effusion as the initial manifestation is exceedingly rare, presenting significant diagnostic and therapeutic challenges. This article reports a case of PMMM that initially manifested as pleural effusion and includes a review of the relevant literature. Case: The patient was admitted with pleural effusion and an anterior mediastinal mass. A pleural biopsy and fine‐needle aspiration of the mediastinal mass led to a pathological diagnosis of malignant melanoma. Ultimately, based on clinical findings, a final diagnosis of PMMM was established. The patient subsequently developed pleural hemorrhage; although hemostasis was achieved through thoracoscopy, his condition stabilized only temporarily. He ultimately succumbed to lung infection and multiple organ failure. Conclusion: PMMM presenting with pleural effusion lacks distinct clinical features, highlighting the importance of pathological diagnosis. Pleural hemorrhage associated with pleural metastasis may be a characteristic feature, and the prognosis for such cases is poor. Enhanced recognition and early intervention are essential to improve outcomes.
- Open Access
- 30 January 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Gorham-Stout disease with thoracic involvement: pathogenic mechanisms, respiratory complications, and multimodal therapies
Background: Gorham-Stout disease (GSD), also known as vanishing bone disease, is a rare osteolytic disorder characterized by progressive bone resorption and proliferation of lymphatic and vascular channels. Thoracic involvement often leads to life-threatening respiratory complications, yet clinical recognition remains delayed due to its rarity and heterogeneity. Objective: This review aims to synthesize recent advances in the understanding of GSD pathogenesis, highlight the disproportionate burden of respiratory complications-particularly chylothorax-and propose an integrated diagnostic and therapeutic framework tailored to anatomical risk profiles. Methods: A comprehensive literature review of 125 cases (2010-2025) was conducted, focusing on molecular mechanisms, clinical phenotypes, respiratory manifestations, and therapeutic outcomes. Key pathogenic pathways involving RANKL/RANK/OPG, M-CSF, VEGF, IL-6, and TNF-α were analyzed, alongside their immune-vascular interactions. Results: Respiratory involvement was observed in over 40% of cases, with chylothorax accounting for the highest mortality risk. Aberrant lymphangiogenesis, immune dysregulation, and osteoclast hyperactivation formed the mechanistic triad driving disease progression. Imaging (CT/MRI/PET) and exclusion-based diagnostics remain essential. Sirolimus-based regimens, bisphosphonates, radiotherapy, and surgical interventions-particularly thoracic duct ligation and vertebral stabilization-comprise the current multimodal strategy. Conclusions: GSD represents a clinically and mechanistically complex entity requiring early identification of respiratory threats, individualized treatment plans, and multidisciplinary coordination. Future research should prioritize biomarker discovery and prospective therapeutic trials to optimize outcomes in this rare but severe condition.
- 30 January 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Open AccessGorham-Stout disease with thoracic involvement: pathogenic mechanisms, respiratory complications, and multimodal therapies
Background: Gorham-Stout disease (GSD), also known as vanishing bone disease, is a rare osteolytic disorder characterized by progressive bone resorption and proliferation of lymphatic and vascular channels. Thoracic involvement often leads to life-threatening respiratory complications, yet clinical recognition remains delayed due to its rarity and heterogeneity. Objective: This review aims to synthesize recent advances in the understanding of GSD pathogenesis, highlight the disproportionate burden of respiratory complications-particularly chylothorax-and propose an integrated diagnostic and therapeutic framework tailored to anatomical risk profiles. Methods: A comprehensive literature review of 125 cases (2010-2025) was conducted, focusing on molecular mechanisms, clinical phenotypes, respiratory manifestations, and therapeutic outcomes. Key pathogenic pathways involving RANKL/RANK/OPG, M-CSF, VEGF, IL-6, and TNF-α were analyzed, alongside their immune-vascular interactions. Results: Respiratory involvement was observed in over 40% of cases, with chylothorax accounting for the highest mortality risk. Aberrant lymphangiogenesis, immune dysregulation, and osteoclast hyperactivation formed the mechanistic triad driving disease progression. Imaging (CT/MRI/PET) and exclusion-based diagnostics remain essential. Sirolimus-based regimens, bisphosphonates, radiotherapy, and surgical interventions-particularly thoracic duct ligation and vertebral stabilization-comprise the current multimodal strategy. Conclusions: GSD represents a clinically and mechanistically complex entity requiring early identification of respiratory threats, individualized treatment plans, and multidisciplinary coordination. Future research should prioritize biomarker discovery and prospective therapeutic trials to optimize outcomes in this rare but severe condition.
- 20 September 2025
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 25 (11) , 1875-1892
Multi-omics Data Integration via Low-Rank Representation and Data Merging for Cancer Subtypes Identification
Integrating multi-omics data from diverse platforms to accurately identify cancer subtypes with similar molecular profiles remains a key challenge in precision medicine. To address this, we introduce a novel approach, Multi-omics Data Low-Rank Representation and Data Merging (MDLRDM), designed to capture both the local and global structures within multi-omics datasets. This method aims to enhance the accuracy and robustness of cancer subtype classification. MDLRDM consists of a two-stage process. In the first stage, a hierarchical weighted matrix is constructed to group samples of the same subtype within each omics data. A low-rank representation is then integrated into this matrix to generate a similarity matrix that reflects the intrinsic relationships between samples. In the second stage, these individual similarity matrices are merged to create a consensus matrix, which is then subjected to spectral clustering for the final identification of cancer subtypes. We evaluated the performance of MDLRDM by comparing it with six state-of-the-art multi-omics integration methods using eight real cancer datasets. The results show that MDLRDM outperforms existing methods in terms of both accuracy and generalizability, providing a more reliable solution for cancer subtype identification. Moreover, the identified subtypes reveal crucial molecular differences that improve our understanding of cancer heterogeneity. These insights not only advance our knowledge of cancer biology but also uncover potential therapeutic targets for clinical intervention.
- 20 September 2025
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 25 (11) , 1875-1892
Multi-omics Data Integration via Low-Rank Representation and Data Merging for Cancer Subtypes Identification
Integrating multi-omics data from diverse platforms to accurately identify cancer subtypes with similar molecular profiles remains a key challenge in precision medicine. To address this, we introduce a novel approach, Multi-omics Data Low-Rank Representation and Data Merging (MDLRDM), designed to capture both the local and global structures within multi-omics datasets. This method aims to enhance the accuracy and robustness of cancer subtype classification. MDLRDM consists of a two-stage process. In the first stage, a hierarchical weighted matrix is constructed to group samples of the same subtype within each omics data. A low-rank representation is then integrated into this matrix to generate a similarity matrix that reflects the intrinsic relationships between samples. In the second stage, these individual similarity matrices are merged to create a consensus matrix, which is then subjected to spectral clustering for the final identification of cancer subtypes. We evaluated the performance of MDLRDM by comparing it with six state-of-the-art multi-omics integration methods using eight real cancer datasets. The results show that MDLRDM outperforms existing methods in terms of both accuracy and generalizability, providing a more reliable solution for cancer subtype identification. Moreover, the identified subtypes reveal crucial molecular differences that improve our understanding of cancer heterogeneity. These insights not only advance our knowledge of cancer biology but also uncover potential therapeutic targets for clinical intervention.
- Open Access
- 15 April 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-18
Translational selenium nanomedicine synergizes with nab-paclitaxel to enhance antitumor effects in esophageal squamous cell cancer via selenoprotein N-mediated ER stress
Though prescribed as first-line drugs for esophageal squamous cell cancer (ESCC) therapy, the antitumor efficacy of Nab-Paclitaxel (Nab-PTX) is still unsatisfactory owing to the limitation on the dosage and therapy duration of Nab-PTX caused by adverse effects. Inspired by the very essential role of Selenoprotein N (SelN) in mediating the calcium homeostasis and the associated redox homeostasis in cells, herein, in this essay, we screened the inhibition effect of selenium-containing drugs in different forms on ESCC cell line. Investigation on KYSE-150 cells demonstrated that Nab-PTX in combination with low dosage of LNT-SeNPs may synergistically improve its antitumor efficacy on ESCC cells through promoting the cellular apoptosis. Proteomics analysis uncovered the core synergistic mechanism of LNT-SeNPs on Nab-PTX was significantly dependent on the endoplasmic reticulum (ER) stress induced by SelN-mediated Ca2+-IRE1α, IRE1α(S724)-CHOP-BCL2 axis. SelN knockdown KYSE-150 cell model further confirmed the very indispensable role of SelN in mediating the synergistic effect on Nab-PTX. Moreover, in vivo evaluation on KYSE-150 tumor-bearing mice models also demonstrated the supplementation of LNT-SeNPs with low dosage during the Nab-PTX treatment may synergize the antitumor efficacy and significantly mitigate the adverse reactions or toxicity resulting from a substantial dose of Nab-PTX. Overall, along with the facile accessibility of raw materials, this study reports LNT-SeNPs as a synergistic agent to promote the antitumor efficacy of Nab-PTX, which may be translated as a wide-applicable, efficient and highly safe strategy for clinical treatment of ESCC.
- 15 April 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-18
Open AccessTranslational selenium nanomedicine synergizes with nab-paclitaxel to enhance antitumor effects in esophageal squamous cell cancer via selenoprotein N-mediated ER stress
Though prescribed as first-line drugs for esophageal squamous cell cancer (ESCC) therapy, the antitumor efficacy of Nab-Paclitaxel (Nab-PTX) is still unsatisfactory owing to the limitation on the dosage and therapy duration of Nab-PTX caused by adverse effects. Inspired by the very essential role of Selenoprotein N (SelN) in mediating the calcium homeostasis and the associated redox homeostasis in cells, herein, in this essay, we screened the inhibition effect of selenium-containing drugs in different forms on ESCC cell line. Investigation on KYSE-150 cells demonstrated that Nab-PTX in combination with low dosage of LNT-SeNPs may synergistically improve its antitumor efficacy on ESCC cells through promoting the cellular apoptosis. Proteomics analysis uncovered the core synergistic mechanism of LNT-SeNPs on Nab-PTX was significantly dependent on the endoplasmic reticulum (ER) stress induced by SelN-mediated Ca2+-IRE1α, IRE1α(S724)-CHOP-BCL2 axis. SelN knockdown KYSE-150 cell model further confirmed the very indispensable role of SelN in mediating the synergistic effect on Nab-PTX. Moreover, in vivo evaluation on KYSE-150 tumor-bearing mice models also demonstrated the supplementation of LNT-SeNPs with low dosage during the Nab-PTX treatment may synergize the antitumor efficacy and significantly mitigate the adverse reactions or toxicity resulting from a substantial dose of Nab-PTX. Overall, along with the facile accessibility of raw materials, this study reports LNT-SeNPs as a synergistic agent to promote the antitumor efficacy of Nab-PTX, which may be translated as a wide-applicable, efficient and highly safe strategy for clinical treatment of ESCC.
- Open Access
- 15 November 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1419750
Analysis of the clinical manifestations and diagnostic process of the pleural effusion associated with constrictive pericarditis
Objectives: The primary objective of this study is to analyze the clinical manifestations, diagnostic procedures, and outcomes of patients with pathologically confirmed constrictive pericarditis who presented with bilateral pleural effusions. We aim to outline a stepwise diagnostic approach that could assist clinicians in identifying CP in similar cases.Methods: In this study, we conducted a retrospective analysis of 19 cases of pathologically confirmed constrictive pericarditis. These patients were admitted to our hospital between January 2019 and December 2022 after pericardial stripping. The collected data included imaging findings, clinical manifestations, pleural effusion characteristics, postoperative pathology, and the diagnostic process.Results: In this study, the age of the 19 patients ranged from 25 to 74 years, with a median age of 59 years. All patients presented with bilateral pleural effusions, with or without pericardial lesions such as pericardial effusion or thickening. Pleural effusion biochemistry did not exhibit specific characteristics, and both etiology and pleural pathology were negative. Radiographic examinations, including cardiac ultrasound and chest CT, revealed signs of pericardial thickening and/or pericardial effusion or no abnormalities. Pericardial stripping was performed in all patients, and the postoperative pathology confirmed various degrees of thickened pericarditis, consistent with constrictive pericarditis. During a follow-up period of 6–18 months, most patients (17 out of 19) showed favorable recovery with no recurrence of bilateral pleural effusions.Conclusion: This study emphasizes the importance of pleural effusion as a clinical sign of constrictive pericarditis and highlights that a stepwise diagnostic approach, guided by clinical presentation and imaging, can enhance its recognition, particularly in cases with bilateral pleural effusions.
- 15 November 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1419750
Open AccessAnalysis of the clinical manifestations and diagnostic process of the pleural effusion associated with constrictive pericarditis
Objectives: The primary objective of this study is to analyze the clinical manifestations, diagnostic procedures, and outcomes of patients with pathologically confirmed constrictive pericarditis who presented with bilateral pleural effusions. We aim to outline a stepwise diagnostic approach that could assist clinicians in identifying CP in similar cases.Methods: In this study, we conducted a retrospective analysis of 19 cases of pathologically confirmed constrictive pericarditis. These patients were admitted to our hospital between January 2019 and December 2022 after pericardial stripping. The collected data included imaging findings, clinical manifestations, pleural effusion characteristics, postoperative pathology, and the diagnostic process.Results: In this study, the age of the 19 patients ranged from 25 to 74 years, with a median age of 59 years. All patients presented with bilateral pleural effusions, with or without pericardial lesions such as pericardial effusion or thickening. Pleural effusion biochemistry did not exhibit specific characteristics, and both etiology and pleural pathology were negative. Radiographic examinations, including cardiac ultrasound and chest CT, revealed signs of pericardial thickening and/or pericardial effusion or no abnormalities. Pericardial stripping was performed in all patients, and the postoperative pathology confirmed various degrees of thickened pericarditis, consistent with constrictive pericarditis. During a follow-up period of 6–18 months, most patients (17 out of 19) showed favorable recovery with no recurrence of bilateral pleural effusions.Conclusion: This study emphasizes the importance of pleural effusion as a clinical sign of constrictive pericarditis and highlights that a stepwise diagnostic approach, guided by clinical presentation and imaging, can enhance its recognition, particularly in cases with bilateral pleural effusions.
- Open Access
- 6 February 2024
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 11 (3) , 1785-1789
Diagnostic Procedure for Localized Constrictive Pericarditis Leading to Bilateral Pleural Effusion: Two Case Reports
Constrictive pericarditis is a rare disease. Localized constrictive pericarditis leading to bilateral pleural effusion is more difficult to recognize, and the diagnostic procedure can be ambiguous. Here, we report two patients diagnosed with localized constrictive pericarditis who presented with bilateral pleural effusion. A thorough work-up showed that the pleural effusion was nonspecific, as was the pathology of the pleura. One patient had a history of pericardial effusion 2 years ago, and the other had undergone surgery for an anterior mediastinum teratoma. Pericardial scarring was found on their chest CT scans. The patients underwent pericardiectomy, and localized pericardial thickening was excised. The bilateral pleural effusion was effectively cured, and the patients showed satisfactory recovery on follow-up. Physicians should be aware of localized pericarditis leading to bilateral pleural effusion, and pericardiectomy is an effective diagnostic and therapeutic procedure.
- 6 February 2024
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 11 (3) , 1785-1789
Open AccessDiagnostic Procedure for Localized Constrictive Pericarditis Leading to Bilateral Pleural Effusion: Two Case Reports
Constrictive pericarditis is a rare disease. Localized constrictive pericarditis leading to bilateral pleural effusion is more difficult to recognize, and the diagnostic procedure can be ambiguous. Here, we report two patients diagnosed with localized constrictive pericarditis who presented with bilateral pleural effusion. A thorough work-up showed that the pleural effusion was nonspecific, as was the pathology of the pleura. One patient had a history of pericardial effusion 2 years ago, and the other had undergone surgery for an anterior mediastinum teratoma. Pericardial scarring was found on their chest CT scans. The patients underwent pericardiectomy, and localized pericardial thickening was excised. The bilateral pleural effusion was effectively cured, and the patients showed satisfactory recovery on follow-up. Physicians should be aware of localized pericarditis leading to bilateral pleural effusion, and pericardiectomy is an effective diagnostic and therapeutic procedure.